AudioMedica
Home of the Audio Journal of OncologyInterviews with the world's key opinion leaders in cancer
EpisodesArchivesAboutHave Your Say

AudioMedica

Connecting healthcare professionals with the latest oncology updates through audio.

Explore

  • Episodes
  • Archives
  • Topics
  • Speakers

Company

  • About Us
  • Have Your Say
  • Contact
  • Privacy Policy

Subscribe

Get the latest updates directly to your inbox.

© 2026 AudioMedica. All rights reserved.

Search

Filters

Topics

Series

Speakers

166 results found in 1ms
      1. Safna Naozer Virji MBBS FPBS; 2025 SABCS: Oncoplastic Breast Cancer Surgery Study Reports High Efficacy with Superior Psychosocial Outcomes in a Low or Middle Income Country Setting
        Audio Journal of Oncology

        Safna Naozer Virji MBBS FPBS; 2025 SABCS: Oncoplastic Breast Cancer Surgery Study Reports High Efficacy with Superior Psychosocial Outcomes in a Low or Middle Income Country Setting

        Oncoplastic breast conserving surgery for breast cancer is practical, effective and very desirable in low and middle income country settings, new research study finds.

        16/01/2026
        Details
      2. Luciano Costa, MD PhD; ASH 2025:  CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard-Risk Relapsed/Refractory Multiple Myeloma
        Audio Journal of Oncology

        Luciano Costa, MD PhD; ASH 2025:  CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard-Risk Relapsed/Refractory Multiple Myeloma

        Luciano Costa MD PhD ASH 2025

        14/01/2026
        Details
      3. Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer  
        Audio Journal of Oncology

        Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer  

        Aromatase inhibitor adjuvant hormone therapy for women with ER+ HER2- early breast cancer performed better than adjuvant treatment with a selective estrogen receptor modifier such as tamoxifen

        09/01/2026
        Details
      4. Jesse Tettero MD PhD; ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia
        Audio Journal of Oncology

        Jesse Tettero MD PhD; ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia

        08/01/2026
        Details
      5. Hisham Abdel-Azim MD MS; ASH 2025: Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation
        Audio Journal of Oncology

        Hisham Abdel-Azim MD MS; ASH 2025: Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation

        Hisham Abdel-Azim MD MS

        06/01/2026
        Details
      6. Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
        Audio Journal of Oncology

        Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings

        A seective estrogen degrader out-performed AI's in ER+ HER- early breast cancer

        18/12/2025
        Details
      7. Daniel J Zheng MD, MHS, MSHP; ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! "Financial Toxicity" is Often More Worrying than your Child's Cancer
        Audio Journal of Oncology

        Daniel J Zheng MD, MHS, MSHP; ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! "Financial Toxicity" is Often More Worrying than your Child's Cancer

        Financial Disaster from curative treatment for childhood ALL

        16/12/2025
        Details
      8. Peihua Lu MD and Robert Chiesa MD PhD; ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies
        Audio Journal of Oncology

        Peihua Lu MD and Robert Chiesa MD PhD; ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies

        Dramatic Cures for Children with No Prospects Using Standard Therapies for T-cell malignancies

        12/12/2025
        Details
      9. Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
        Audio Journal of Oncology

        Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer

        Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring for the return of the disease was carried out.

        01/12/2025
        Details
      10. Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
        Audio Journal of Oncology

        Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer

        Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy

        24/11/2025
        Details
      11. Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
        Audio Journal of Oncology

        Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy

        Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

        19/11/2025
        Details
      12. Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer
        Audio Journal of Oncology

        Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer

        ADC beats SOC in previously treated Advanced Breast Cancer

        14/11/2025
        Details
      • ‹‹
      • ‹
      • 1
      • 2
      • 3
      • 4
      • 5
      • ›
      • ››